Difference between revisions of "Relugolix (Orgovyx)"
m (Jwarner moved page Relugolix (Relumina) to Relugolix (Orgovyx): FDA approval with new brand name) |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| − | |||
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 00:04, 16 April 2021
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with relugolix, in contrast to GnRH agonists.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 12/18/2020: Approved for adult patients with advanced prostate cancer.
Also known as
- Code name: TAK-385
- Brand names: Orgovyx, Relumina